Nucleus Global

nucleus-global.com

Nucleus Global is the largest privately held medical communications company in the world. Built on a reputation of scientific excellence and quality, we are a global leader in delivering world-class, innovative education and medical marketing services to the pharmaceutical and biotechnology industries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

COUR PHARMACEUTICALS RECEIVES FDA FAST TRACK DESIGNATION FOR CNP-104 FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

COUR Pharmaceuticals | January 11, 2022

news image

COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders, today announced the U.S. Food and Drug Administration granted Fast Track Designation to the Company's investigational therapy CNP-104 for the treatment of Primary Biliary Cholangitis. CNP-104 aims to reprogram the immune system to address autoimmune causes of PBC. "We are pleased to have received Fast Track Designation for CN...

Read More

Business Insights

NOVO NORDISK TO ACQUIRE FORMA THERAPEUTICS AND EXPAND PRESENCE IN SICKLE CELL DISEASE AND RARE BLOOD DISORDERS

Novo Nordisk | September 02, 2022

news image

Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. The acquisition of Forma Therapeutics, including its lead developm...

Read More

ALTO, A PHARMACY START-UP, JUST RAISED $250 MILLION FROM SOFTBANK’S VISION FUND 2 AND OTHERS

CNBC: | January 30, 2020

news image

Alto Pharmacy has raised $250 million from investors including SoftBank’s second Vision Fund, three people familiar with the matter told CNBC. The investment has already been approved by the Vision Fund’s investment committee, meaning it’s a done deal, the sources said. It also marks one of the first handful of known bets from the SoftBank’s new fund. The deal values the company at more than $700 million, according to one of the people. SoftBank’s Vision Fund has al...

Read More

Business Insights

MILLIPORESIGMA INVESTS $ 286 MILLION IN U.S. DRUG SAFETY TESTING CAPACITY

MilliporeSigma | November 16, 2022

news image

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its Life Science business sector is investing more than $ 286 million in its biosafety testing capacity at the company's site in Rockville, Maryland, USA. This will significantly increase the company's ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fund...

Read More
news image

Pharma Tech

COUR PHARMACEUTICALS RECEIVES FDA FAST TRACK DESIGNATION FOR CNP-104 FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

COUR Pharmaceuticals | January 11, 2022

COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders, today announced the U.S. Food and Drug Administration granted Fast Track Designation to the Company's investigational therapy CNP-104 for the treatment of Primary Biliary Cholangitis. CNP-104 aims to reprogram the immune system to address autoimmune causes of PBC. "We are pleased to have received Fast Track Designation for CN...

Read More
news image

Business Insights

NOVO NORDISK TO ACQUIRE FORMA THERAPEUTICS AND EXPAND PRESENCE IN SICKLE CELL DISEASE AND RARE BLOOD DISORDERS

Novo Nordisk | September 02, 2022

Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. The acquisition of Forma Therapeutics, including its lead developm...

Read More
news image

ALTO, A PHARMACY START-UP, JUST RAISED $250 MILLION FROM SOFTBANK’S VISION FUND 2 AND OTHERS

CNBC: | January 30, 2020

Alto Pharmacy has raised $250 million from investors including SoftBank’s second Vision Fund, three people familiar with the matter told CNBC. The investment has already been approved by the Vision Fund’s investment committee, meaning it’s a done deal, the sources said. It also marks one of the first handful of known bets from the SoftBank’s new fund. The deal values the company at more than $700 million, according to one of the people. SoftBank’s Vision Fund has al...

Read More
news image

Business Insights

MILLIPORESIGMA INVESTS $ 286 MILLION IN U.S. DRUG SAFETY TESTING CAPACITY

MilliporeSigma | November 16, 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its Life Science business sector is investing more than $ 286 million in its biosafety testing capacity at the company's site in Rockville, Maryland, USA. This will significantly increase the company's ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fund...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us